Skip to content
Search

Latest Stories

Pharmacy Business Diversity Conference - session summary: 'Improving ethnic diversity in workplace is a never-ending journey'

The journey on building inclusive teams and increasing ethnic diversity and representation at all levels is never ending, said Sanjay Bhandari, chair at Kick It Out.

“I think you can set the direction but it's quite difficult to set the destination with these things,” Bhandari, who is part of the government-sponsored Parker review into the ethnic diversity of UK boards said during a panel discussion on Inclusive Leadership held as part of the Pharmacy Business Diversity Conference on Thursday (December 9).


He said the aim of the review was to fix a destination like a milestone, it's not the ultimate destination.

Bhandari highlighted that “most organizations have not even started and so a good way of getting started was by the end of 2021 to have at least one British born director of color on your board for the FTSE 100 (companies).”

The idea of the review is to “focus on that pathway and filling the hole in the doughnut,” Bhandari said.

There is a need to modernize the leadership style to meet the diversity and inclusion goals, he added.

“I think it's about asking and not assuming it's about demonstrating some empathy. And it's about converting those behaviors into tangible activities.”

The session was moderated by the conference chair BBC presenter Clive Myrie, joined by Ravi Chand CBE, director, Places for Growth and Beyond at the Cabinet Office and Antonio Bebba, regional operations lead for Pfizer’s Diversity, Equity & Inclusion Council Europe (DICE).

Approving the recommendations of the Parker review, Chand said it's really important for people at the top to “set the tone and expectation.”

He added there is a need to change the system in terms of hiring.

“You have to change the system. Otherwise you can get very enlightened individuals right across the organisation, operating the very machinery that still discriminates and creates less favourable outcomes for people of colour”.

Bebba added that leadership is essential to bring key changes in the company’s culture.

This ideology drove Pfizer to add equity as its one of the company’s values, in 2019.

He said: “Our final goal is to be sure that all the colleagues that are working at Pfizer from when they enter in the company until when they leave, they experience inclusion in all the way around a 360 degree.

“Working with intersectionality allows you to make sure that everyone is included in the conversation.

After achieving a balanced representation of all communities in the company, Pfizer aims to ensure that they feel included in value, in the decision making process and be an integral part of the current change, Bebba added.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less